INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
1 - 82 . (canceled)
83 . A reassortant influenza virus comprising a polynucleotide selected from the group consisting of:
a) a polynucleotide comprising the nucleotide sequence of any one of SEQ ID NO:36-48, or a complementary sequence thereof; and
b) a polynucleotide sequence encoding a polypeptide comprising the amino acid sequence of any one of SEQ ID NO:84-96, or a complementary polynucleotide sequence thereof.
84 . The virus of claim 83 , wherein the virus is a 6:2 reassortant virus, which virus comprises 6 internal genome segments from one or more donor virus and 2 genome segments comprising a polynucleotide comprising the nucleotide sequence of any one of SEQ ID NO:36-48.
85 . The virus of claim 84 , wherein the donor virus is A/Ann Arbor/6/60, B/Ann Arbor/1/66, A/Puerto Rico/8/34, B/Leningrad/14/17/55, B/14/5/1, B/USSR/60/69, B/Leningrad/179/86, B/Leningrad/14/55, or B/England/2608/76.
86 . An immunogenic composition comprising an immunologically effective amount of the reassortant influenza virus of claim 84 .
87 . A vaccine comprising the immunogenic composition of claim 86 .
88 . The virus of claim 83 , wherein the virus is a 7:1 reassortant virus, which virus comprises 7 genome segments from one or more donor virus and 1 genome segment comprising a polynucleotide comprising the nucleotide sequence of any one of SEQ ID NO:36-48.
89 . The virus of claim 83 , wherein the virus is one or more of: a temperature-sensitive virus, a cold-adapted virus, or an attenuated virus.
90 . The virus of claim 88 , wherein the donor virus is A/Ann Arbor/6/60, B/Ann Arbor/1/66, A/Puerto Rico/8/34, B/Leningrad/14/17/55, B/14/5/1, B/USSR/60/69, B/Leningrad/179/86, B/Leningrad/14/55, or B/England/2608/76.
91 . The virus of claim 84 , wherein the 6:2 reassortant virus is a live virus.
92 . A method for producing the reassortant influenza virus of claim 83 comprising:
introducing a plurality of vectors comprising nucleic acids corresponding to an influenza virus genome into a population of host cells, which influenza virus genome comprises at least 6 internal genome segments of a first influenza strain, and at least one genome segment of a second influenza strain, wherein the at least one genome segment of the second influenza strain comprises a polynucleotide comprising the nucleotide sequence of any one of SEQ ID NO:36-48, and wherein the population of host cells is capable of supporting replication of influenza virus;
culturing the population of host cells; and
recovering a plurality of influenza viruses.
93 . The method of claim 92 , wherein the first influenza virus strain is at least one of: an attenuated influenza virus strain, a cold-adapted influenza virus strain, and a temperature-sensitive influenza virus strain.
94 . The method of claim 92 , wherein the influenza viruses are suitable for administration in an intranasal vaccine formulation.
95 . The method of claim 92 , wherein the influenza virus genome is an influenza A virus genome or influenza B virus genome.
96 . The method of claim 92 , wherein the first influenza strain is selected from the group consisting of A/Ann Arbor/6/60, B/Ann Arbor/1/66, A/Puerto Rico/8/34, B/Leningrad/14/17/55, B/14/5/1, B/USSR/60/69, B/Leningrad/179/86, B/Leningrad/14/55, or B/England/2608/76.
97 . The method of claim 92 , wherein the plurality of vectors are plasmid vectors.
98 . The method of claim 92 , wherein the population of host cells comprises one or more of: Vero cells, cells deposited under ECACC No. 96022940, MDCK cells, 293T cells, or COS cells.
99 . The method of claim 92 , wherein the method does not comprise use of a helper virus.
100 . The method of claim 92 , wherein the plurality of vectors consists of eight vectors.